IDH1 and central nervous system cancer: Neomorphic mutations in isocitrate dehydrogenase (IDH) enzymes (arginine 132 for IDH1 and arginine 172 for IDH2) are found in 70% of gliomas and are highly associated with favorable outcomes of glioma patients [1].